within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07F_BetaBlockingAgentsOtherCombinations.C07FB03_AtenololAndNifedipine;

model AtenololAndNifedipine
  extends Pharmacolibrary.Drugs.ATC.C.C07FB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C07FB03</td></tr><td>route:</td><td></td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Combination of atenolol, a selective beta-1 adrenergic blocker, and nifedipine, a dihydropyridine calcium channel blocker. Used for the management of hypertension and angina pectoris. The drug is approved and used in clinical practice today, particularly when single-agent therapy is insufficient.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic studies or population PK models published for the fixed dose combination of atenolol and nifedipine (ATC C07FB03) were found. Individual pharmacokinetics for each agent are well-characterized, but specific combination PK parameters are not reported in the literature for healthy or patient populations.</p><h4>References</h4><ol><li><p>Gangji, D, et al., &amp; Herchuelz, A (1984). Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol. <i>British journal of clinical pharmacology</i> 17 Suppl 1(Suppl 1) 29S–35S. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1984.tb02425.x\">10.1111/j.1365-2125.1984.tb02425.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6146337/\">https://pubmed.ncbi.nlm.nih.gov/6146337</a></p></li><li><p>Fitzsimons, TJ, et al., &amp; McAinsh, J (1991). A study of the pharmacokinetics and pharmacodynamics of nifedipine in combination with atenolol. <i>Biopharmaceutics &amp; drug disposition</i> 12(1) 81–94. DOI:<a href=\"https://doi.org/10.1002/bdd.2510120109\">10.1002/bdd.2510120109</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2039814/\">https://pubmed.ncbi.nlm.nih.gov/2039814</a></p></li><li><p>Rosenkranz, B, et al., &amp; Frölich, JC (1986). Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. <i>Journal of cardiovascular pharmacology</i> 8(5) 943–949. DOI:<a href=\"https://doi.org/10.1097/00005344-198609000-00010\">10.1097/00005344-198609000-00010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2429095/\">https://pubmed.ncbi.nlm.nih.gov/2429095</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AtenololAndNifedipine;
